Table 2.
List of publications of allogenic mesenchymal stem cells application for cartilage repair.
| Author Year Study Type |
Number of Patients | Stem Cell Origin | Number of Cells | Control Group | Follow-up Time | Co-Treatment | Delivery System | Assessments |
|---|---|---|---|---|---|---|---|---|
| Vangsness et al. Randomized, double-blind, controlled study [157] |
36 | Allogenic BM-MSCs from 18–30-year old donors |
5.0 × 107, 1.5 × 108 |
20 cell free vehicle control |
24 months | Partial medial meniscectomy | Intra-articular injection | Measurement of immune cell markers; MRI; VAS; Lysholm score |
| Vega et al. Randomized control trial [158] |
15 | Allogenic BM-MSCs |
40 × 106 | 15 Hyaluronic acid (60 mg, single dose) |
12 months | None | Intra-articular injection | VAS, WOMAC, SF-12; MRI |
| De Windt et al. Case series study [159] |
10 | Allogenic BM-MSCs from the iliac crest of 2 healthy donors (age 2 and 5) |
N/A. Mixed cells in the fibrinogen component of fibrin glue at 1.5–2 × 106 cells/mL | 10% or 20% autologous chondrons (a standard or a high yield mixture) |
12 months | None | Defect site-specific implantation | KOOS, VAS; Second-look arthroscopy; Histological analysis; |
| De Windt et al. Case series study [160] |
35 | Allogenic cryopreserved BM-MSCs |
N/A. Mixed cells in the fibrinogen component of fibrin glue at 1.5–2 × 106 cells/mL. Approximately 0.9 mL cell product/cm2 defect | 10% or 20% autologous chondrons (a standard or a high yield mixture) |
18 months | None | Defect site-specific implantation | KOOS, VAS; Second-look arthroscopy; Histological analysis; |
BM-MSCs: bone marrow-derived mesenchymal stem cells; KOOS: the Knee Injury and Osteoarthritis Outcome; MRI: magnetic resonance imaging; N/A: not available; SF-12: short form-12 life quality questionnaire; VAS: visual analogue pain scale; WOMAC: the Western Ontario and McMaster Universities Arthritis Index.